Rilpivirine: Difference between revisions
Created page with " {{intro}} Rilpivirine is a nonnucleoside reverse transcriptase inhibitor used in combination with other antiretroviral agents in the therapy of human immunodeficiency virus (..." |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
[[File:Rilpivirine.svg|Rilpivirine|thumb]] | |||
[[File:Rilpivirine 3D 2zd1.png|Rilpivirine 3D Structure|thumb]] | |||
[[File:Rilpivirine metabolism example.svg|Rilpivirine Metabolism Example|thumb]] | |||
{{intro}} | {{intro}} | ||
Rilpivirine is a nonnucleoside reverse transcriptase inhibitor used in combination with other antiretroviral agents in the therapy of human immunodeficiency virus ([[HIV]]) infection. | Rilpivirine is a nonnucleoside reverse transcriptase inhibitor used in combination with other antiretroviral agents in the therapy of human immunodeficiency virus ([[HIV]]) infection. | ||
{{livtox}} | {{livtox}} | ||
Rilpivirine is associated with a low rate of transient serum [[aminotransferase]] elevations during therapy and has been implicated in rare cases of clinically apparent acute [[liver injury]]. | Rilpivirine is associated with a low rate of transient serum [[aminotransferase]] elevations during therapy and has been implicated in rare cases of clinically apparent acute [[liver injury]]. | ||
{{moa}} | {{moa}} | ||
Rilpivirine (ril" pi vir' een) is an antiretroviral agent that acts by noncompetitive binding to, and inhibition of the [[HIV]] reverse transcriptase. Rilpivirine is a nonnucleoside reverse transcriptase inhibitor similar in action to nevirapine, efavirenz, delavirdine and etavirine. In several randomized controlled trials, rilpivirine was found to have similar efficacy to efavirenz when combined with at least two nucleoside analogues (typically tenofovir and emtricitabine). Rilpivirine was the fifth nonnucleoside reverse transcriptase inhibitor approved by the FDA [2011], and current indications are for the treatment of [[HIV]] infection in combination with other [[HIV]] medications. | Rilpivirine (ril" pi vir' een) is an antiretroviral agent that acts by noncompetitive binding to, and inhibition of the [[HIV]] reverse transcriptase. Rilpivirine is a nonnucleoside reverse transcriptase inhibitor similar in action to nevirapine, efavirenz, delavirdine and etavirine. In several randomized controlled trials, rilpivirine was found to have similar efficacy to efavirenz when combined with at least two nucleoside analogues (typically tenofovir and emtricitabine). Rilpivirine was the fifth nonnucleoside reverse transcriptase inhibitor approved by the FDA [2011], and current indications are for the treatment of [[HIV]] infection in combination with other [[HIV]] medications. | ||
{{dose}} | {{dose}} | ||
Rilpivirine is available under the brand name Edurant in tablets of 25 mg. The recommended dose is 25 mg orally once daily with a meal. Rilpivirine is also available in a fixed dose combination (25 mg) once a day tablet with emtricitabine (200 mg) and tenofovir disoproxil fumarate (300 mg) under the brand name Complera [2011] and a similar combination with tenofovir alafenamide fumarate (25 mg) under the brand name Odefsey [2016]. Antiviral resistance can occur and resistance patterns are similar to, and cross react with those due to other nonnucleoside reverse transcription inhibitors. | Rilpivirine is available under the brand name Edurant in tablets of 25 mg. The recommended dose is 25 mg orally once daily with a meal. Rilpivirine is also available in a fixed dose combination (25 mg) once a day tablet with emtricitabine (200 mg) and tenofovir disoproxil fumarate (300 mg) under the brand name Complera [2011] and a similar combination with tenofovir alafenamide fumarate (25 mg) under the brand name Odefsey [2016]. Antiviral resistance can occur and resistance patterns are similar to, and cross react with those due to other nonnucleoside reverse transcription inhibitors. | ||
{{se}} | {{se}} | ||
Common side effects include fatigue, [[dizziness]], [[headache]], insomnia, depression and [[skin rash]]es. | Common side effects include fatigue, [[dizziness]], [[headache]], insomnia, depression and [[skin rash]]es. | ||
{{antiviral agents}} | {{antiviral agents}} | ||
{{coststubd}} | {{coststubd}} | ||
{{Antiretroviral drug}} | |||
{{Portal bar | Medicine | Viruses }} | |||
[[Category:Non-nucleoside reverse transcriptase inhibitors]] | |||
[[Category:Nitriles]] | |||
[[Category:Pyrimidines]] | |||
[[Category:Drugs developed by Johnson & Johnson]] | |||
Latest revision as of 03:49, 22 March 2025
Information about Rilpivirine[edit]
Rilpivirine is a nonnucleoside reverse transcriptase inhibitor used in combination with other antiretroviral agents in the therapy of human immunodeficiency virus (HIV) infection.
Liver safety of Rilpivirine[edit]
Rilpivirine is associated with a low rate of transient serum aminotransferase elevations during therapy and has been implicated in rare cases of clinically apparent acute liver injury.
Mechanism of action of Rilpivirine[edit]
Rilpivirine (ril" pi vir' een) is an antiretroviral agent that acts by noncompetitive binding to, and inhibition of the HIV reverse transcriptase. Rilpivirine is a nonnucleoside reverse transcriptase inhibitor similar in action to nevirapine, efavirenz, delavirdine and etavirine. In several randomized controlled trials, rilpivirine was found to have similar efficacy to efavirenz when combined with at least two nucleoside analogues (typically tenofovir and emtricitabine). Rilpivirine was the fifth nonnucleoside reverse transcriptase inhibitor approved by the FDA [2011], and current indications are for the treatment of HIV infection in combination with other HIV medications.
Dosage and administration for Rilpivirine[edit]
Rilpivirine is available under the brand name Edurant in tablets of 25 mg. The recommended dose is 25 mg orally once daily with a meal. Rilpivirine is also available in a fixed dose combination (25 mg) once a day tablet with emtricitabine (200 mg) and tenofovir disoproxil fumarate (300 mg) under the brand name Complera [2011] and a similar combination with tenofovir alafenamide fumarate (25 mg) under the brand name Odefsey [2016]. Antiviral resistance can occur and resistance patterns are similar to, and cross react with those due to other nonnucleoside reverse transcription inhibitors.
Side effects of Rilpivirine[edit]
Common side effects include fatigue, dizziness, headache, insomnia, depression and skin rashes.
Antiviral agents[edit]
Drugs for HIV Infection, in the Subclass Antiretroviral Agents
- Fusion Inhibitors (HIV)
- Integrase Inhibitors (HIV)
- Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
- Interferon Based Therapies
HCV NS5A Inhibitors
HCV NS5B (Polymerase) Inhibitors
- Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir
Combination Therapies
Drugs for Herpes Virus Infections (HSV, CMV, others)
Drugs for Influenza
| Antiviral drugs: antiretroviral drugs used against HIV (primarily J05) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
